Chemerin in Liver Diseases

doi:10.4172/2161-1017.1000144

Cited by 4 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemerin is abundant in adipocytes and hepatocytes and circulating chemerin levels were increased in obese patients (37). Previous studies have reported that circulating chemerin was not changed in HCC serum whereas its levels were induced in CRC patients (19,56,57). Our recent study showed comparable chemerin levels in the HCC and CRC patients with liver metastases (30).…”

Section: Discussionsupporting

confidence: 48%

Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors

et al. 2019

View full text Add to dashboard Cite

Background/Aim: Adiponectin protects from metabolic disease and cancer. Accordingly, serum adiponectin was reduced in patients with colorectal cancer (CRC). This hepatoprotective factor was definitely increased in hepatocellular carcinoma (HCC). CRC metastases to the liver are common and the aim of the present study was to evaluate whether serum adiponectin discriminates primary from secondary liver cancers. Materials and Methods: Adiponectin was measured by ELISA in the serum of 36 patients with colorectal liver metastases, 32 patients with HCC and 49 patients without cancer. Results: Serum adiponectin levels were higher in cancer than non-tumor patients. Adiponectin was not related to TNM stage in HCC nor to the levels of serum tumor markers. Moreover, hepatic inflammation and liver fibrosis were not correlated with serum adiponectin levels. Metabolic diseases are associated with low adiponectin and a higher risk of cancer. In HCC, but not in CRC serum, adiponectin was increased in patients with hypertension and hyperuricemia. In this cohort, adiponectin positively correlated with chemerin, an adipokine supposed to contribute to metabolic disturbances. Conclusion: Serum adiponectin cannot discriminate primary from secondary liver tumors.

show abstract

Section: Discussionsupporting

confidence: 48%

Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…2 SD = standard deviation. 3 Self-reported measures. Eleven data points missing/unknown/declined to state for the self-reported duration of diabetes, and four data points missing/unknown/declined to state for the smoking status.…”

Section: Participant Characteristicsmentioning

confidence: 99%

“…Chemerin, also known as retinoic acid receptor responder protein 2 (RARRES2) or TIG2, is an adipokine and immunomodulator encoded by the RARRES2 gene [1][2][3][4][5][6]. This adipokine is synthesized as an inactive precursor that undergoes activation and a subsequent inactivation through a series of proteolytic cleavages [7,8].…”

Section: Introductionmentioning

confidence: 99%

Chemerin Levels in Individuals with Type 2 Diabetes and a Normal Weight versus Individuals with Type 2 Diabetes and Obesity: An Observational, Cross-Sectional Study

Mukherji,

Idowu,

Zhao

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Chemerin acts as both a chemotactic agent and an adipokine that undergoes proteolytic cleavage, converting inactive precursors into their active forms before being subsequently inactivated. Elevated chemerin levels are linked to obesity and type 2 diabetes mellitus (T2D). This study aimed to elucidate the effects of T2D and obesity on chemerin levels by comparing plasma samples from individuals with a normal weight and T2D (BMI < 25; NWD group n = 22) with those from individuals who are overweight or obese and have T2D (BMI ≥ 25; OWD group n = 39). The total chemerin levels were similar in the NWD and OWD groups, suggesting that T2D may equalize the chemerin levels irrespective of obesity status. The cleavage of chemerin has been previously linked to myocardial infarction and stroke in NWD, with potential implications for inflammation and mortality. OWD plasma exhibited lower levels of cleaved chemerin than the NWD group, suggesting less inflammation in the OWD group. Here, we showed that the interaction between obesity and T2D leads to an equalization in the total chemerin levels. The cleaved chemerin levels and the associated inflammatory state, however, differ significantly, underscoring the complex relationship between chemerin, T2D, and obesity.

show abstract